Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses

Blood

Volumn 100, Issue 12, 2002, Pages 4169-4176

  Weigel, Brenda J ^a,b,c,d   Nath, Narender ^a,b,c,d   Taylor, Patricia A ^a,b,c,d   Panoskaltsis Mortari, Angela ^a,b,c,d   Chen, Wei ^a,b,c,d   Krieg, Arthur M ^a,b,c,d   Brasel, Kenneth ^a,b,c,d   Blazar, Bruce R ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c PFIZER INC   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANINE; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MEMBRANE ANTIGEN; OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; VACCINATION;

EID: 0036892761     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1063     Document Type: Article

References (65)

1. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A. 1998;95:9482-9487.
2. Zitvogel LZ, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87-97.
3. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J Exp Med. 1997;186:1177-1182.
4. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulse dendritic cells. Nat Med. 1998;4:328-332.
5. Bender A, Sapp M, Feldman M, et al. Dendritic cells as immunogens for human CTL responses. Adv Exp Med Biol. 1997;417:383-387.
6. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
7. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study. Blood. 1999;93:2411-2419.
8. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173-180.
9. Salgaller ML, Tjoa BA, Lodge PA, et al. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol. 1998;18:109-119.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
11. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
12. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423-433.
13. Sozzani S, Allavena P, D'Amico G, et al. Cutting edge: Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties. J Immunol. 1998;161:1083-1086.
14. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373-386.
15. Mitchell DA, Nair SK, Gilboa E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. EurJ Immunol. 1998;28:1923-1933.
16. Inaba K, Young JW, Steinman RM. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J Exp Med. 1987;166:182-194.
17. Braun SE, Aronica SM, Ge Y, et al. Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells. Exp Hematol. 1997;25:51-56.
18. Brasel K, McKenna HJ, Morrissey PJ, et al. Hematologic effects of fit3 ligand in vivo in mice. Blood. 1996;88:2004-2012.
19. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol. 1997;159:2222-2231.
20. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953-1962.
21. Pawlowska AB, Hashino S, McKenna H, et al. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells proved protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood. 2001;97:1474-1482.
22. Brasel K, De Smedt T, Smith JL, et al. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood. 2000;96:3029-3039.
23. Kreig AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000;12:35-43.
24. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ. Immune recognition of foreign DNA: A cure for bioterrorism. Immunity. 1999;11:123-129.
25. Wagner H. Bacterial CpG DNA activated immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368.
26. Weiner GJ, Lul HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effects as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997;94:10833-10837.
27. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B-cells. J Immunol. 2000;164:944-953.
28. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89:2994-2998.
29. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998;161:2428-2434.
30. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186:1623-1631.
31. Klinman DM, Yi AK, Baucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996;93:2879-2883.
32. Hartmann G, Weiner G, Krieg AM. CpG DNA as a signal for growth, activation and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;96:9305-9310.
33. Jakob T, Walker PS, Krieg AM, Dudey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory CAN. J Immunol. 1998;161:3042-3049.
34. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28:2045-2054.
35. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001;98:1217-1225.
36. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factors. J Exp Med. 1992;176:1693-1702.
37. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162:168-175.
38. Boyer MW, Orchard PJ, Gorden KB, Anderson PM, McIvor RS, Blazar BR. Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia. Blood. 1995;85:2498-2506.
39. Matzinger P. The JAM test: A simple assay for DNA fragmentation and cell death. J Immunol Methods. 1991;145:185-192.
40. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies, I: Data analysis. J Immunol. 1981;126:1614-1619.
41. Brunner C, Seiderer J, Schlamp A. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000;165:6278-6286.
42. + T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-β. J Immunol. 1999;163:3684-3691.
43. Schnare M, Barton GM, Czopik Holt A, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947-950.
44. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237-9242.
45. Hemmi H, Takuechi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
46. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
47. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996;6:133-139.
48. Kadowaki N, Ho S,Antonenko S, de Waal Malefyt R, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
49. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31:3026-3037.
50. + cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. Eur J Immunol. 2002;32:686-692.
51. + cells in mouse lymph nodes and spleen display characteristics of plasmacytold dendritic cells. J Exp Med. 2001;194:1171-1178.
52. Bjorck P. Isolation and characterization of plasmacytoid dendritic cells from flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood. 2001;98:3520-3526.
53. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-ligand administration inhibits liver metastases: Role of NK cells. J Immunol. 1998;161:6164-6170.
54. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 1998;15:3647-3657.
55. Ciavarra RP, Somers KD, Brown RR, et al. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res. 2000;60:2081-2084.
56. Lynch DH. Induction of dendritic cells by Flt3 ligand promotes the generation of tumor-specific immune responses in vivo. Crit Rev Immunol. 1998;18:99-107.
57. Wang A, Braun SE, Sonpavde G, Cornetta K. Antileukemia activity of Flt3 ligand in murine leukemia. Cancer Res. 2000;60:1895-1900.
58. Morse MA, Nair S, Fernandez-Casal M, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol. 2000;18:3883-3893.
59. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Fit3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98:8809-8814.
60. Gilliet M, Boonstra A, Paturel C, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med. 2002;195:953-958.
61. O'Connell PJ, Li W, Wang Z, Specht SM, Logar AJ, Thomson AW. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol. 2002;168:143-154.
62. Liu YJ. Dendritic cell subsets and lineages and their functions in innate and adaptive immunity. Cell. 2001;106:259-262.
63. Merad M, Fong L, Bogenberger J, et al. Differentiation of myeloid dendritic cells into CD8α-positive dendritic cells in vivo. Blood. 2000;96:1865-1872.
64. low lymphoid-committed precursors. Blood. 2000;96:2511-2519.
65. Manz MG, Traver D, Miyamoto T, et al. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood. 2001;97:3333-3341.